New York, June 22, 2026, 18:03 (EDT)
Nexentis Technologies Inc. shares soared more than 100% on Monday after a new AI drug-discovery update hit the tape. The small Nasdaq-listed name drew heavy trading interest for most of the session, though the stock pulled back some in after-hours trade.
Shares ended the regular session at $13.00, up 155.91%. The stock traded from $11.00 to $23.80. Trading volume came in at 60.3 million shares, far above the 65-day average of 198,960. A delayed MarketWatch quote showed the stock falling 26.15% after hours to $9.60.
Shares jumped after two market-sensitive items: a research deal targeting AI-based drug discovery and word of a fresh stock-and-warrant financing. Those moves can pull fast money into thin biotech trades, but they also push investors to square the potential from big science headlines with dilution risk.
Nexentis said its MitoCareX Bio unit is working with Boltz, an AI research group focused on biomolecular models, to look for small-molecule starting points tied to chosen solute carrier proteins. These proteins move substances across cell membranes. CEO David Palach said the MITOLINE platform provides “target-specific structural insight”. Boltz brings AI that could speed up finding starting points. GlobeNewswire
The company says its software models can help pick out drug-like compounds before researchers head into expensive lab work. That’s the pitch. It’s not proof of a drug that actually works.
Nexentis said in an 8-K after the close that it will sell 410,998 common shares at $7.056 apiece in a registered direct offering. The deal includes the same number of five-year warrants for buyers to purchase shares later at a fixed price. Nexentis expects gross proceeds of about $2.9 million before expenses, with the offering set to close around June 24.
Stock priced under Monday’s close, setting a tone for Tuesday trading. More cash on hand may support projects, but more shares and warrants could cut into current holders’ stakes if triggered.
Competition is tight. Recursion Pharmaceuticals calls itself a clinical-stage “TechBio” company with a platform that maps out biological and chemical connections. Schrödinger uses a physics-driven computational platform for drug discovery and other material uses. Nexentis is smaller, earlier-stage, and is also in renewable energy projects. Reuters
Nexentis’s latest quarterly filing broke out results in two pieces, biotechnology and renewable energy. The company had $4.3 million cash and equivalents at March 31, and posted a net loss of $6.6 million for the first quarter. Management also flagged a going-concern risk. The filing said there was substantial doubt about Nexentis’s ability to stay in business if it doesn’t secure more funding.
That’s the risk for shareholders. The stock might keep going if momentum traders stick around or Nexentis posts more research milestones. The downside is clear: Boltz work may not produce good drug candidates, the company could need more money, and more equity sales might hit the share price.
U.S. stocks struggled for direction as markets reopened after the three-day weekend. The S&P 500 slipped 0.4%. The Nasdaq Composite dropped 1.3%. Small-caps outperformed, with the Russell 2000 up 0.8%.
Monday’s rally now faces the test of the financing overhang. Nexentis has managed to push its stock up off an AI research release, but the market is looking for more lasting gains.
